Dasiglucagon
Also known as: Zegalogue, ZP4207
Stable glucagon analog in a ready-to-use injection, FDA-approved in 2021 as Zegalogue for severe hypoglycemia in diabetes. Prescription medication.
Last updated
Mechanism of Action
Dasiglucagon is a glucagon analog with seven amino acid substitutions that make it stable and soluble in an aqueous solution, so it does not need to be mixed before injection or form fibrils like native glucagon. It activates the glucagon receptor on liver cells, triggering glycogen breakdown and glucose release into the blood. This raises blood glucose within minutes during severe hypoglycemia.
- Half-life
- ~30 minutes
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Rapid treatment of severe hypoglycemia in adults and children with diabetes
- Ready-to-use autoinjector or prefilled syringe with no reconstitution
- Studied for preventing hypoglycemia in congenital hyperinsulinism
Potential Side Effects
- Nausea and vomiting
- Headache
- Injection-site pain
- Hypertensive crisis risk in pheochromocytoma (warning)
Common Dosing
Labeled use is a single 0.6 mg subcutaneous rescue dose for severe hypoglycemia, which a caregiver can give; a second dose may be given if there is no response, and emergency help should be sought. Prescribing and training are supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Pheochromocytoma
- Insulinoma
No documented stacking partners for Dasiglucagon yet.
- View
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
2021
- View
Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
2021
- View
Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children
2024